Table 2.
Odds ratios for relevant comorbidities and drug prescriptions of relevant pharmacotherapies in girls with a CSA experience registration compared to controls 1 (1–365 days) and 2 years (366–730 days) after the first registered CSA experience (2011–2018)
| Diagnoses | OR 1 year after diagnosis n = 519 (CI 95%) | OR 2 years after diagnosis n = 519 (CI 95%) |
|---|---|---|
| Psychosis (F20, F23, F25, F28, F29) | 19.39 (1.75–214.13) | 9.0 (1.36–68.95) |
| Suicide attempt (× 6) | 26.38 (12.65–55.02) | 6.93 (3.48–13.49) |
| Stress (F43) | 25.97 (17.42–38.69) | 15.63 (9.82–24.88) |
| Alcohol abuse (F10) | 10.32 (6.48–16.44) | 6.40 (3.88–10.55) |
| Depression (F32, F33) | 4.67 (3.30–6.60) | 3.02 (2.08–4.39) |
| Anxiety (F 40, F41) | 4.59 (3.45–6.09) | 3.46 (2.54–4.72) |
| Autism (F.84) | 3.18 (1.86–5.46) | 3.72 (2.15–6.44) |
| ADHD (F90) | 3.85 (2.86–5.18) | 3.65 (2.70–4.93) |
| Pain (R10, R51, R52, G44, M79) | 1.63 (1.28–2.07) | 1.55 (1.21–1.99) |
| Eating disorders (F50) | 1.66 (0.70–3.97) | 2.05 (0.95–4.42) |
| Bipolar disorder (F30, F31) | 3.23 (0.65–16.05) | 2.65 (0.74–9.51) |
| Borderline (F60) | 2.42 (0.27–21.67) | 6.09 (1.98–18.67) |
| Pharmaceutical drug type | ||
| Tranquilizers (R06AD02, N05BB) | 8.37 (6.58–10.64) | 5.81 (4.40–7.66) |
| NRLP (N05A) | 10.92 (6.47–18.43) | 8.93 (5.38–14.84) |
| Propiomazine (N05CM06) | 7.55 (4.63–12.32) | 8.11 (5.22–12.61) |
| Antidepressant drugs (N06A) | 7.34 (5.79–9.31) | 5.51 (4.30–7.05) |
| Melatonin (N05CH01) | 6.26 (4.88–8.05) | 4.48 (3.33–6.03) |
| Hypnotics (N05CF) | 9.88 (4.56–21.43) | 3.40 (1.51–7.64) |
| Stimulants (N06BA) | 4.13 (3.12–5.47) | 4.67 (3.54–6.17) |
| Benzodiazepines (N05CD, N05BA) | 3.38 (1.64–6.97) | 2.16 (0.89–5.26) |